You are here:

raltegravir (Isentress)

Advice

Following a full submission

raltegravir (Isentress) is accepted for restricted use within NHS Scotland in combination with other antiretroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV-1) infection in treatment experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. It is restricted to patients with triple class resistant HIV-1 infection.

Addition of raltegravir to optimised background therapy in treatment experienced patients with documented resistance to at least one drug in each of the three HIV antiviral classes, significantly increased the number of patients achieving clinically significant reductions in viral load.

Drug Details

Drug Name: raltegravir (Isentress)
SMC Drug ID: 461/08
Manufacturer: MSD
Indication: in combination with other antiretroviral medicinal products agents for the treatment of Human Immunodeficiency Virus (HIV-1) infection in treatment experienced adult patients
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Restricted
Date Advice Published: 12 May 2008

Back